IP Verse

Nuclease-Independent Targeted Gene Editing Platform And Uses Thereof

Patent No. EP3322804 (titled "Nuclease-Independent Targeted Gene Editing Platform And Uses Thereof") was filed by Rutgers on Jul 15, 2016. The application was issued on Sep 1, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BEAM THERAPEUTICSMay 31, 2022HGF
STRAWMANMay 31, 2022FINNEGAN EUROPE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3322804

RUTGERS
Application Number
EP16825229A
Filing Date
Jul 15, 2016
Status
Granted And Under Opposition
Jul 30, 2021
Publication Date
Sep 1, 2021
External Links
Slate, Register , Google Patents